New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 12, 2014
04:55 EDTPRGO, PRGO, QSII, QSII, PKI, PKI, AMAG, AMAG, AMBI, AMBI, LLY, LLY, WAT, WAT, CSII, CSII, BLUE, BLUELeerink to hold a conference
2014 Global Healthcare Conference is being held in New York on February 12-13.
News For PRGO;QSII;PKI;AMAG;AMBI;LLY;WAT;CSII;BLUE From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
May 19, 2015
08:57 EDTBLUEPiper sees upside to LentiGlobin launch expectations
Piper Jaffray sees upside potential to its expectation that LentiGlobin will launch in 2020 after the bluebird bio this morning provided a regulatory update. Piper believes approval in Europe for treatment of beta-thal major could come as much as three years earlier than expected while approval in the U.S. is likely to be ahead of expectations as well. The firm reiterates an Overweight rating on bluebird with a $186 price target.
08:21 EDTBLUEbluebird bio approval may come sooner than expected, says JPMorgan
JPMorgan analyst Cory Kasimov reiterates an Overweight rating on bluebird bio after the company announced this morning regulatory plans for LentiGlobin in B-thalassemia in the U.S. and Europe. Kasimov says approval could come earlier than the firm's current 2019 estimate with bluebird seeking accelerated approval in both geographies. The analyst recommends remaining a buyer of the stock ahead of the B-thalassemia data in June. Shares of the clinical-stage biotechnology company are up $5.60 to $162 in pre-market trading.
06:08 EDTPRGOPerrigo CEO says would talk with Mylan, but at a higher price, Globes reports
Subscribe for More Information
06:05 EDTBLUEbluebird bio discusses potential approval pathways for LentiGlobin BB305
Subscribe for More Information
May 18, 2015
12:07 EDTPRGOPerrigo: there is price point where would engage with Mylan, Bloomberg reports
Subscribe for More Information
07:22 EDTPKI, WATUBS to hold a conference
Global Healthcare Conference is being held in New York on May 18-20 with webcasted company presentations to begin on May 18 at 8 am; not all company presentations may be webcasted. Webcast Link
06:55 EDTAMAGAMAG Pharmaceuticals price target raised to $85 from $60 at Leerink
Leerink raised its price target for AMAG Pharmaceuticals to $85 on expectations the 1mL vial formulation will help accelerate Makena's market share gain. The firm reiterates an Outperform rating on the stock.
May 14, 2015
09:22 EDTLLYLeerink pharma/biotech analysts hold an analyst/industry conference call
Subscribe for More Information
07:44 EDTLLYInternational Headache Society to hold a conference
17th Congress of the International Headache Society is being held in Valencia, Spain on May 14-17.
06:04 EDTLLYEli Lilly, Sanford-Burnham to investigate immunological therapies
Subscribe for More Information
May 13, 2015
13:40 EDTBLUEbluebird bio June volatility elevated on wide price movement
Subscribe for More Information
May 12, 2015
08:52 EDTPKIPerkinElmer management to meet with Leerink
Subscribe for More Information
08:48 EDTPRGOPerrigo acquires Patheon's Mexican operations for $34M
Subscribe for More Information
07:52 EDTAMAGLeerink to hold a tour
Subscribe for More Information
May 11, 2015
15:19 EDTLLYEli Lilly, BioNTech enter into research collaboration
Eli Lilly and BioNTech announced they have entered into a research collaboration to discover novel cancer immunotherapies. The companies will seek to use the power of the body's own immune system to attack cancer cells and create possible new treatment options for cancer patients. Leveraging the scientific expertise between the two organizations, Lilly and BioNTech will collaborate to identify and validate novel tumor targets and their corresponding T cell receptors in one or more types of cancer. These tumor targets and TCRs may then be engineered and developed into potent and selective cancer therapies. Under the terms of the agreement, BioNTech will receive a $30M signing fee. For each potential medicine, BioNTech could receive over $300M in development, regulatory and commercial milestones. If successfully commercialized, BioNTech would also be eligible for tiered royalty payments up to double-digits. In addition, subject to the terms of the agreement, Lilly will make a $30M equity investment in BioNTech's subsidiary, Cell & Gene Therapies GmbH, which specializes in the research and development of TCR and chimeric antigen receptor immunotherapeutics. Further financial terms were not disclosed.
14:34 EDTBLUEbluebird bio June volatility elevated on sharp rally
bluebird bio May call option implied volatility is at 73, June is at 109, August is at 82; compared to its 90-day average of 86, suggesting large near term price movement.
11:53 EDTPRGOTeva rejected chance to acquire Perrigo a few months ago, Globes reports
Subscribe for More Information
07:51 EDTBLUEConference should be positive turning point for bluebird bio, says SunTrust
SunTrust expects data due to be released at the EHA conference to create a positive turning point for bluebird bio. The firm notes that the data will include information on a sickle cell patient treated with bluebird's LentiGlobin, and the firm thinks that LentiGlobin is an effective sickle cell treatment. The firm now includes sickle cell in its estimates for the company and raised its price target on the shares to $205 from $115. It keeps a Buy rating o nthe stock.
May 8, 2015
10:44 EDTBLUEOptions with increasing implied volatility
Subscribe for More Information
06:16 EDTPRGOHorizon Pharma announces Pennsaid 2% patent litigation with Perrigo
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use